Based on recent safety and efficacy data, combined with the known pharmacokinetic parameters of aminoglycosides in the newborn, oncedaily gentamicin should be preferable to the many other dosing regimens currently in use. Although there are growing data to support its use in term newborns, experience with preterm infants is more limited. In our Neonatal Intensive Care Unit, we experienced difficulties regarding complicated dosing regimens, actual dosing errors, and the tendency to check trough and peak levels around the third dose for infants receiving only a 48 hour course. Therefore, we conducted a quality improvement initiative in which we developed and tested a clinical practice guideline for the use of once-daily gentamicin for preterm and term infants that we hoped would yield trough and peak levels in our target range.
INTRODUCTION
Gentamicin is an aminoglycoside antibiotic commonly used in the Neonatal Intensive Care Unit (NICU) to treat infants with normal renal function who demonstrate signs or symptoms concerning for bacterial infection. There is considerable variation in dosing regimens throughout the country; in the NICU at Children's Hospital, Boston, a common dose had been 2.5 mg/kg every 12 to 36 hours depending on gestational age. With this regimen, we experienced several problems: (1) potential increased toxicity associated with elevated troughs; (2) potential decreased efficacy associated with suboptimal peaks; (3) potential error due to complicated dosing intervals; (4) increased cost associated with additional doses, including cost of serum levels and personnel as well as medication.
The institution of a once-daily gentamicin dosing regimen could address all of these problems. In the neonatal population, there is considerable data supporting once-daily gentamicin dosing in term infants where it appears to have an attractive safety [1] [2] [3] [4] [5] [6] [7] and efficacy [1] [2] [3] [4] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] profile. Because of the difference in both clearance and volume of distribution in preterm infants, it is known that the dosing of aminoglycosides must take gestational age into consideration. 5, 18 Yet the data for preterm infant is more limited. 4, [19] [20] [21] [22] Therefore, in the context of a quality improvement initiative, we elected to design a clinical practice guideline for gentamicin dosing that would provide simple and standardized treatment for both preterm and term newborns. In designing the dose and interval, our specific goals were to yield a low trough of r2 mg/ml and a high peak of 6 to 12 mg/ml, to minimize potential for errors in calculating dose and intervals, and to minimize unnecessary testing (obtaining levels when third dose occurs during a 48 hour ''rule-out'').
Although some authors have advocated use of a loading dose in order to achieve early high peaks, 2 we elected to omit this, because it would substantially complicate an otherwise simple regimen, and there is adequate data that therapeutic peaks can be achieved without a loading dose. 6, 8 
METHODS
We reviewed the published English literature regarding once daily gentamicin dosing for term and preterm infants. Multiple studies have assessed pharmacokinetics, serum levels, safety and efficacy of once-daily gentamicin dosing in term infants. [1] [2] [3] [4] [5] [6] 8, 18 The data regarding once-daily dosing for preterm infants 4,19 -22 is more limited, with small sample sizes, especially in the lower gestational ages. [19] [20] [21] [22] We concluded from the literature that a dose of 4 mg/kg for term infants yields the highest proportion of both troughs and peaks within our target range. For infants <35 weeks gestation, the limited literature supported a dose of <4 mg/kg.
We then analyzed our own trough and peak data from 25 patients who had received gentamicin based on dosing of 2.5 mg/ kg at variable dosing intervals depending on gestational and postnatal age. Pharmacokinetic parameters were calculated to determine the gentamicin half-life and volume of distribution in these patients. Using these pharmacokinetic parameters, we extrapolated the data to determine what the trough and peak levels would be at with various doses if given once a day. The data supported a dose of 4 mg/kg for term infants and 3 mg/kg/day for infants <35 weeks gestation. Therefore, based on our review of the literature and our own data, we developed a clinical practice guideline for once-daily gentamicin dosing for term and preterm infants (see Figure 1) .
After the clinical practice guideline had been implemented, we conducted a case series study to determine if it yielded trough and peak levels in our target range. We measured trough and peak levels as well as collected available blood urea nitrogen (BUN) and creatanine (Cr) data for all NICU patients receiving gentamicin for at least 72 hours based on this new dosing regimen between 3/1/99 and 12/31/00.
Exclusion criteria:
(1) paired trough and peak level not available; (2) incorrect dose for weight (±10% to account for rounding and accuracy of pharmacy measurements); (3) multiple levels from same patient (we included only the first pair of levels to avoid over-representation of sicker patients).
Gentamicin was infused over 30 minutes. Serum trough levels were drawn immediately before starting the subsequent infusion. Serum peak levels were drawn 30 minutes after completion of the infusion. Gentamicin levels were performed using fluorescence polarization immunoassay methodology. The lower limit detectable by the assay is 0.14 mg/ml.
We reviewed the charts of all babies with nonstandard timing for collection of trough or peak sample, and with elevated trough or nontherapeutic peak levels in order to determine if data were incorrect. We excluded cases when the trough and peak appeared to have been switched, and when the sample was actually a random level rather than a trough or peak.
We obtained approval from our Investigational Review Board to conduct this study. We did not obtain informed consent because there is not an accepted standard gentamicin dose from which we were deviating. The regimen implemented was similar to previously described and published regimens and was reasonable based on pharmacokinetic analysis. We elected not to collect data regarding error rate of calculating a 24 hour interval, as it has been previously demonstrated that simplified intervals result in fewer errors. 2 It was also beyond the scope of this quality-improvement project to reproduce the extensive literature addressing the correlation between low troughs and safety 1, 7 or high peaks and efficacy. [9] [10] [11] [12] [13] [14] [15] [16] [17] Since there is currently not a broadly accepted gentamicin dosing protocol, we felt that a comparison with our previous ''historical controls'' who received gentamicin prior to the introduction of this clinical practice guideline would have reflected a wide range of dosing practices and rendered an arbitrary comparison. Therefore, our ''gold standard'' was our trough and peak goals.
RESULTS
During the study dates, 370 NICU patients were treated with gentamicin in the first week of life, 290 of whom had a complete set of levels measured (the remainder of whom received only a 48 hour course with levels, appropriately, not checked). After excluding babies based on our criteria, 214 remained. Of these, 75 were <35 weeks gestation and 139 were at least 35 weeks gestation (see Table 1 for sample characteristics).
Troughs. No babies had troughs >2 mg/ml, leaving 100% of infants with trough levels r2 mg/ml regardless of gestational age. For infants of gestational age <35 weeks, the mean trough was 1.1 mg/ml, with a range of 0.2 to 1.9 mg/ml. For infants of at least 35 weeks gestation, the mean trough was 0.9 mg/ml and the range was 0.1 to 2.0 mg/ml. (see Table 2 and Figure 2) .
Peaks. For infants of gestational age <35 weeks, 79% had therapeutic peak levels (defined to be between 6 and 12 mg/ml), with a mean of 6.8 mg/ml, and a range of 4.7 to 9.1 mg/ml. A total of 93% of infants of at least 35 weeks gestation had therapeutic peak levels, with a mean of 8.4, and a range of 4.0 to 18.0 mg/ml (see Table 2 and Figure 2) . Notably, of 26 babies with nontherapeutic peaks, in 24 cases, or 92%, the peak was too low.
Renal function. We analyzed available BUN and Cr values for all study patients. If multiple samples were sent for BUN and/or Cr, we included in our analysis the sample drawn latest in the course of gentamicin treatment. In total, 86% of patient had at least one BUN and Cr level measured. Five patients, or 2.7% of patients in whom BUN was measured, had a value above the upper limits of normal (defined by our laboratory as 25). The BUN mean was 10.6, with a standard deviation of 6.0, and a range of 1.0 to 38.0. Similarly, nine patients, or 4.9% in whom Cr was measured, had a Cr above the upper limits of normal (defined by our laboratory as 1.0). The Cr mean was 0.5, the standard deviation was 0.2, and the range was 0.1 to 1.5. Pharmacokinetic extrapolation. Because the majority of undesirable serum levels were low peaks in the 31 to 35 week gestation infants, we conducted a pharmacokinetic analysis of our own to data to extrapolate what serum levels would be generated by a 3.5 mg/kg once-daily dosing regimen in this group. Anticipating that this higher dose might yield an unacceptable proportion of elevated troughs, especially in the 31 to 32 week gestation group, we also analyzed what levels would be generated by the 3.5 mg/kg dose if given every 36 hours (see Table 3 ). Increasing the oncedaily dose from 3.0 to 3.5 mg/kg improved the percentage of peaks in the desired range from 73 to 100%, but decreased the percentage of troughs in the desirable range from 100 to 86%. A dose of 3.5 mg/kg given every 36 hours yielded 100% of peaks and troughs in the desired range.
DISCUSSION
Although the details are debated, there is consensus that toxicity is minimized by attaining a low trough level obtained with long intervals, and efficacy is maximized by attaining a high peak level obtained with high doses. The large volume of distribution and slow elimination of the newborn makes this the ideal population to benefit from the attributes of once-daily dosing, namely high doses given at prolonged intervals.
The literature amply supports once-daily dosing in term newborns, and the dose of 4 mg/kg is gaining acceptance. Dosing for preterm infants remains controversial. Our study presents the largest published sample size to date of preterm infants receiving once daily gentamicin and supports the dose of 3 mg/kg as yielding a high proportion of troughs and peaks within our target range.
The low overall rate of elevated BUN and/or Cr supports the previously demonstrated safety of once daily gentamicin dosing. [1] [2] [3] [4] [5] [6] [7] The infants at the margin of our transition from preterm to term, namely those in the 31 to 35 week gestation range had the highest proportion of low peaks. If one wanted to sacrifice the simplicity of the regimen to further fine-tune the dosing, based on pharmaco-kinetic principles this could be addressed in two different ways. One option would be to lower the gestational age at which one transitions from the ''term'' to the ''preterm'' dose. Though this preserves the simplicity of two dosing groups, it would be expected to increase the trough level of the gestationally youngest group in the higher dosing range, possibly out of the acceptably safe range.
The other option would be to develop the middle group into a third category that might be best served with an intermediate dose.
We found that a dose of 3.5 mg/kg given every 36 hours yields the highest proportion of peaks and troughs in the desired range (see Table 3 ). Figure 2 . Foaks and troughs for gentamicin by gestational age Comparison of real data from 31 to 35 week gestation infants given 3 mg/kg q 24 hours (first column) with extrapolated data generated by pharmacokinetic analysis if dose (second column) and frequency (third column) were increased.
Overall, our simple once-daily gentamicin dosing regimen successfully meets our goals; it provides an extremely low rate of elevated troughs and a high rate of therapeutic peaks. Its oncedaily characteristic theoretically reduces potential for error of interval calculation 2 as well as time and cost of administration. 4, 23 
